Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00620620 · ClinicalTrials.gov registry record · Phase 1
Staccato Zaleplon Single Dose Pharmacokinetics
A Phase 1 study, sponsored by Alexza Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00620620 is a Phase 1 study that has completed, run by Alexza Pharmaceuticals. The registered enrollment target is 40 participants.
The verdict
NCT00620620, a Phase 1 study, has completed, sponsored by Alexza Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the safety, tolerability and pharmacokinetics of zaleplon delivered by the Staccato thermal aerosol system in healthy volunteers
Interventions
- DRUG Inhaled placebo
- DRUG Inhaled Zaleplon 0.5 mg
- DRUG Inhaled Zaleplon 1 mg
- DRUG Inhaled Zaleplon 2 mg
- DRUG Inhaled Zaleplon 4 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-02 |
| Est. Completion | 2008-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00620620
The ClinicalTrials.gov registry entry for NCT00620620 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexza Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Inhaled placebo is the first listed.
NCT00620620 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00620620 about?
NCT00620620 is a clinical study titled "Staccato Zaleplon Single Dose Pharmacokinetics". The purpose of the study is to determine the safety, tolerability and pharmacokinetics of zaleplon delivered by the Staccato thermal aerosol system in healthy volunteers
What is the current status of trial NCT00620620?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2008-02. Estimated completion is 2008-03.
What interventions are being tested in trial NCT00620620?
The interventions under investigation include: Inhaled placebo (DRUG), Inhaled Zaleplon 0.5 mg (DRUG), Inhaled Zaleplon 1 mg (DRUG), Inhaled Zaleplon 2 mg (DRUG), Inhaled Zaleplon 4 mg (DRUG).
Who is sponsoring clinical trial NCT00620620?
This trial is sponsored by Alexza Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.